BIOQUÉBEC, MONTRÉAL INVIVO AND SHERBROOKE INNOPOLE JOIN THEIR VOICES IN A LETTER ADDRESSED TO THE PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB)

On December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.

Letter of opinionsGuest UserDecember 9, 2022BIOOQuébecBIOQuébec, Life Sciences, healthcare, pmprb

Resilient Healthcare Coalition : Building Stronger Canadian Health Care Systems

Looking to catalyze a vital cross-government policy conversation at the dawn of a new mandate for the Government of Canada, the Resilient Healthcare Coalition (RHC) has taken the liberty of drafting a proposed Joint Mandate Letter.

Request to postpone decision on July 15, 2021 PMPRB Guidelines changes

As leaders of eight of Canada’s provincial health and life sciences organizations, we are writing to express concerns about the PMPRB’s impending decision on the above-noted proposed Guidelines changes. We strongly believe you should postpone any decisions related to this initiative for several important reasons.

Letter of opinionsGuest UserOctober 22, 2021PMPRB

Proposed TRIPS Waiver for Intellectual Property

On behalf of the member companies of the biotechnology and life sciences organizations across Canada, we are writing on this occasion to urge the government to oppose the TRIPS waivers proposal before the World Trade Organization which would allow countries to force the transfer of intellectual property and know-how on covid-19 vaccines. The proposed waiver fundamentally undermines the very system that produced the current group of COVID-19 vaccines and will be a disincentive for the investors and companies taking risks to develop solutions for the next health emergency.

Canada should be on the frontlines of developing and manufacturing new vaccines, therapies and other technologies, so we can enjoy those everyday moments.

Canada should be on the frontlines of developing and manufacturing new vaccines, therapies and other technologies, so we can enjoy those everyday moments. Prime Minister, we can work with you to build a world-class life sciences sector to make this happen.

Letter of opinionsGuest UserApril 12, 2021canadian collaboration, Justin Trudeau, Health